VNDA FY 2021 Earnings Report — Vanda Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena

Vanda Pharmaceuticals Inc.VNDA

FY 2021 Earnings

Reported February 24, 2022

Quarter Comparison

Revenue

Operating Income

Gross Margin

Net Margin

EPS (Diluted)

Free Cash Flow

Metric	FY 2021	Prior Q	FY 2020	QoQ Change	YoY Change
Revenue	$269M	—	$248M	—	8.3%
Op. Income	$42M	—	$27M	—	54.8%
Gross Margin	90.5%	—	90.6%	—	-0.1pp
Net Margin	12.3%	—	9.4%	—	2.9pp
EPS (Diluted)	$0.58	—	$0.42	—	38.1%
Free Cash Flow	$64M	—	$50M	—	27.4%

Revenue Flow

Item	Amount
REVENUE	$269M
Cost of Revenue	$26M
GROSS PROFIT	$243M
R&D Expenses	$75M
Selling & Marketing	$7M
General & Administrative	$117M
SG&A Expenses	$124M
Other Expenses	$1M
Operating Expenses	$201M
Cost & Expenses	$227M
OPERATING INCOME	$42M
Interest Income	$199.0K
Interest Expense	$0
Other Income/Expenses	$199.0K
INCOME BEFORE TAX	$42M
Income Tax Expense	$9M
Net Income from Continuing Ops	$33M
Net Income from Discontinued Ops	$0
Other Adjustments	$0
NET INCOME	$33M
Net Income Deductions	$0
BOTTOM LINE NET INCOME	$33M
D&A	$3M
EBIT	$42M
EBITDA	$45M
EPS	$1
EPS Diluted	$1

Income Statement

Item	Amount
REVENUE	$269M
Cost of Revenue	$26M
GROSS PROFIT	$243M
R&D Expenses	$75M
Selling & Marketing	$7M
General & Administrative	$117M
SG&A Expenses	$124M
Other Expenses	$1M
Operating Expenses	$201M
Cost & Expenses	$227M
OPERATING INCOME	$42M
Interest Income	$199.0K
Interest Expense	$0
Other Income/Expenses	$199.0K
INCOME BEFORE TAX	$42M
Income Tax Expense	$9M
Net Income from Continuing Ops	$33M
Net Income from Discontinued Ops	$0
Other Adjustments	$0
NET INCOME	$33M
Net Income Deductions	$0
BOTTOM LINE NET INCOME	$33M
D&A	$3M
EBIT	$42M
EBITDA	$45M
EPS	$1
EPS Diluted	$1

Cash Flow Statement

Item	Amount
Net Income	$33M
Depreciation & Amortization	$3M
Stock-Based Compensation	$15M
Deferred Income Tax	$7M
Other Non-Cash Items	$3M
Change in Working Capital	$3M
OPERATING CASH FLOW	$64M
Capital Expenditure	-$552.0K
Acquisitions (Net)	$0
Purchases of Investments	-$420M
Sales/Maturities of Investments	$344M
Other Investing Activities	$0
NET CASH FROM INVESTING	-$77M
Net Debt Issuance	$0
Common Stock Repurchased	$0
Common Dividends Paid	$0
Other Financing Activities	$0
NET CASH FROM FINANCING	$4M
FREE CASH FLOW	$64M
Net Change in Cash	-$9M

Balance Sheet

Item	Amount
Cash & Equivalents	$52M
Short-Term Investments	$381M
Net Receivables	$32M
Inventory	$1M
Other Current Assets	$0
TOTAL CURRENT ASSETS	$478M
PP&E (Net)	$12M
Goodwill	$0
Intangible Assets	$20M
Long-Term Investments	$0
Tax Assets	$75M
Other Non-Current Assets	$8M
TOTAL NON-CURRENT ASSETS	$115M
TOTAL ASSETS	$594M
Account Payables	$925.0K
Short-Term Debt	$0
Deferred Revenue	$0
Other Current Liabilities	$28M
TOTAL CURRENT LIABILITIES	$74M
Long-Term Debt	$0
Deferred Revenue NC	$0
Deferred Tax Liabilities	$0
Other Non-Current Liabilities	$4M
TOTAL NON-CURRENT LIABILITIES	$14M
TOTAL LIABILITIES	$89M
Common Stock	$56.0K
Additional Paid-In Capital	$669M
Retained Earnings	-$164M
Treasury Stock	$0
Accum. Other Comp. Income	-$175.0K
Other Equity	$0
TOTAL STOCKHOLDERS' EQUITY	$505M
Minority Interest	$0
TOTAL EQUITY	$505M
TOTAL LIABILITIES & EQUITY	$594M
Total Debt	$12M
Net Debt	-$40M